1.055

1.92% 0.015

Actinium Pharmaceuticals Inc (ATNM)

Overview News Price History Option Chain Discussions Forecast Stock Split

Actinium Pharmaceuticals Inc stock is traded at $1.055, with a volume of 310.29K. It is up +1.92% in the last 24 hours and up +14.98% over the past month. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Previous Close:

$1.04

Open:

$1.11

24h Volume:

310.29K

Relative Volume:

2.39

Market Cap:

$33.10M

Revenue:

$90,000

Net Income/Loss:

$-23.47M

P/E Ratio:

-1.4026

EPS:

-0.7522

Net Cash Flow:

$-22.98M

1W Performance:

+37.63%

1M Performance:

+14.98%

6M Performance:

-1.85%

1Y Performance:

-37.28%

1-Day Range:

$1.05

$1.13

1-Week Range:

$0.7701

$1.13

52-Week Range:

$0.7351

$1.8059

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name

Actinium Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

646-767-3870

Address

275 Madison Avenue, 7th Floor, New York, NY

Employee

Twitter

@actiniumpharma

Next Earnings Date

2026-08-14

Latest SEC Filings

ATNM's Discussions on Twitter

Compare ATNM vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATNM Actinium Pharmaceuticals Inc	1.055	32.63M	90,000	-23.47M	-22.98M	-0.7522
VRTX Vertex Pharmaceuticals Inc	515.67	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.59	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	993.07	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.47	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral
May-14-24	Initiated	Stephens	Overweight
Sep-06-23	Initiated	HSBC Securities	Buy
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight
Aug-25-22	Initiated	B. Riley Securities	Buy
Nov-05-20	Initiated	Alliance Global Partners	Buy
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy
Oct-23-17	Resumed	ROTH Capital	Buy
Sep-14-17	Initiated	Maxim Group	Buy
Aug-25-16	Initiated	ROTH Capital	Buy
Feb-29-16	Initiated	H.C. Wainwright	Buy
Oct-15-15	Initiated	FBR Capital	Outperform
Oct-01-14	Initiated	MLV & Co	Buy
Jul-22-14	Initiated	Canaccord Genuity	Buy

View All

Actinium Pharmaceuticals Inc Stock (ATNM) Latest News

Aug 14, 2026

Form 8K Actinium Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update - TradingView

Aug 14, 2026

Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Aug 14, 2026

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - PR Newswire

Aug 14, 2026

Aug 12, 2026

Actinium Pharmaceuticals (ATNM) Institutional Ownership 2026 - marketbeat.com

Aug 12, 2026

Aug 03, 2026

Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. (ATNM) InvestorsLead Plaintiff Deadline on May 27, 2025 - The National Law Review

Aug 03, 2026

Aug 01, 2026

Actinium Pharmaceuticals, Inc. (Delaware) Revenue Breakdown – AMEX:ATNM - TradingView

Aug 01, 2026

Jul 28, 2026

Actinium Pharmaceuticals (ATNM) Edges Higher as Stock Holds Above Key SupportSector ETF Flow - dars.gov.et

Jul 28, 2026

Jul 27, 2026

Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM)Join by May 27, 2025Contact Levi & Korsinsky - The National Law Review

Jul 27, 2026

Jul 26, 2026